Recently, the possibility of inhibiting tumour cell signals arising from the activation of VEGFR2 has been demonstrated through several pharmacodynamic approaches, including receptor blockade (ramucirumab), seizure of the ligand (bevacizumab), and use of small-molecule inhibitors (sorafenib, sunitinib, apatinib, cediranib, and telatinib) [12]. Here, KDR is linked to neoplasm.